Investor Highlights

  • Oncology indications collectively represent a large market opportunity addressing numerous unmet medical needs
  • Strong management team with deep industry expertise retaining all upside phases of drug development
  •   Significant public company expertise
  • Management continues to build a strong pipeline by actively reviewing synergistic in-licensing opportunities
  •   Robust ongoing business development effort
  • Capital efficient model due to in-licensing strategy focused on derisked assets with clear path to market
  • Potential to build commercialization capability in the indications being pursued, therefore retaining all upside